Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.
Veradigm Inc. (MDRX) is a healthcare technology company that focuses on healthcare data and technology solutions for providers, payers, and biopharma organizations. News about Veradigm often centers on how the company uses its platforms, data, connectivity, and expertise within the Veradigm Network to support clinical, operational, and financial performance in healthcare.
Investors and industry observers following MDRX news can expect updates on business performance, financing, and capital structure, as reflected in Veradigm’s announcements about financial outlooks, cash and debt levels, and debt financing arrangements. The company also issues news about its progress on financial reporting, including the filing of its Annual Report on Form 10-K with restated financial statements and its efforts to become current in SEC filings and pursue relisting on a national stock exchange.
Operational and client-focused news includes case studies and collaborations that highlight Veradigm’s role in value-based care, payer–provider integration, and revenue cycle management. Examples include recognition through a KLAS Points of Light Award for delivering insights at the point of care and announcements about organizations selecting Veradigm Revenue Cycle Services, Coding Services, and related offerings such as Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath.
Veradigm also issues news on product and capability developments, such as applying artificial intelligence to deidentified EHR data to generate real-world evidence for GLP-1 therapies, and on thought leadership initiatives like the Smart Medicine Podcast. Governance and corporate updates, including leadership appointments and amendments to the company’s stockholder rights plan, are additional recurring themes. For a comprehensive view of MDRX-related developments, this news page aggregates these announcements and related coverage in one place.
Pulse8 has announced that its Qualit8 solution achieved MY2022 Measure Certification from the National Committee for Quality Assurance (NCQA) for the third consecutive year. This certification highlights the solution’s commitment to enhancing administrative efficiency and delivering value to health plan customers. The NCQA-Certified HEDIS Measurement Program offers various certifications, including Health Plan Measures and Hybrid Sampling. Veradigm's dedication to transparent analytics aims to reduce healthcare spending and waste while improving efficiency for its clients.
Veradigm, a unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), has received a patent for its innovative "Dynamic Intervention Planning" method. This system enhances risk adjustment programs by enabling clients to identify, assess, and prioritize opportunities effectively. According to Tom Langan, the company aims to reduce waste and improve accuracy in revenue predictions, thereby allowing better management of client programs. Veradigm uniquely positions itself in the market by controlling significant aspects of risk adjustment, which can lead to greater financial returns for health plans.
Allscripts (MDRX) announced that researchers from Veradigm will present health economics and outcomes research data on Covid-19, diabetes, NASH, and cardiovascular disease at ISPOR 2022 in Washington, D.C., from May 15-18, 2022. Key presentations will focus on real-world data to improve public health initiatives, including the Covid-19 Dashboard to guide outreach to underserved communities. Veradigm aims to harness diverse data sources for better clinical outcomes and decision-making. This research could enhance understanding of disease risk factors and public health response.
On May 5, 2022, Allscripts Healthcare Solutions (MDRX) announced its Q1 2022 financial results, revealing a GAAP diluted EPS of $0.17 and a non-GAAP diluted EPS of $0.13. The company generated $35 million in cash flow from continuing operations and reported Veradigm revenue of $136 million, up from $126 million in Q1 2021. Consolidated GAAP net income reached $23 million, a significant increase from $9 million last year. The company confirmed its annual outlook, expecting Veradigm revenue growth of 6% to 7% and adjusted EBITDA growth of 10% to 15%.
Allscripts Healthcare Solutions (NASDAQ:MDRX) has finalized the sale of its Hospital and Large Physician Practices business to Constellation Software Inc.'s subsidiary, N. Harris Computer Corporation. This strategic move aims to enhance Allscripts' focus on high-growth markets, thereby providing greater value to clients, employees, and shareholders, according to President and CFO Rick Poulton. The transition also includes potential risks related to earnings and management attention diversions, reflecting on Allscripts' future performance expectations.
Allscripts Healthcare Solutions (NASDAQ:MDRX) will release its financial results for Q1 2022 on May 5, 2022, after market close. The earnings announcement will be followed by a conference call at 4:30 p.m. Eastern Time to discuss the results. Interested participants can access the call through the Allscripts Investor Relations website or by dialing 877-269-7756. A replay will be available for four weeks post-call. Allscripts specializes in healthcare information technology solutions aimed at improving clinical and operational outcomes.
Allscripts (NASDAQ: MDRX) has relaunched its Application Store, now called the Allscripts App Expo, enhancing accessibility for clients to discover certified applications developed through the Allscripts Developer Program. The platform expands the visibility of certified solutions built with Allscripts APIs, promoting interoperability. Allscripts continues to support connectivity across various environments and specialties, with hundreds of certified apps available. The company’s commitment to innovation is evidenced by participation in upcoming industry events, including ViVE 2022 and HIMSS 2022.
Allscripts Healthcare Solutions (NASDAQ: MDRX) has agreed to sell its Hospitals and Large Physician Practices business segment to Constellation Software Inc. through its subsidiary N. Harris Computer Corporation for up to $700 million. The deal consists of a fixed payment of $670 million at closing and contingent consideration of up to $30 million based on performance over two years. This transaction aims to enhance focus and opportunities for Allscripts' clients and shareholders, with the sale expected to finalize in the second quarter, pending regulatory approval.
Veradigm, part of Allscripts Healthcare Solutions (MDRX), has announced a partnership with the U.S. Social Security Administration (SSA) to enhance the speed of health record retrieval. This new system will reduce retrieval time from weeks or days to just minutes for millions of patient-authorized requests. The Veradigm eChart Courier™ will automate the request process, decreasing administrative burdens on healthcare providers while improving the experience for SSA applicants.
Allscripts Healthcare Solutions (MDRX) reported a fourth quarter 2021 GAAP diluted EPS of $0.68, with non-GAAP diluted EPS at $0.79. Bookings rose 21% to $219 million compared to Q4 2020. The company generated $66 million in cash flow from continuing operations, while total revenue increased to $392 million, up from $386 million in the same quarter last year. Net income for Q4 2021 was $87 million, a decrease from $728 million in Q4 2020, primarily due to prior year gains from divestitures. Looking forward, Allscripts anticipates 2022 consolidated free cash flow between $165 million and $175 million and revenue growth of 1% to 2%.